Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

(NASDAQ:ZYBT) Zhengye Biotechnology Holding Limited announced its unaudited financial results for the six months ended June 30, 2026. Net revenue was RMB50.9 million (US$7.5 million) for the period, down from RMB62.3 million in the same period last year. Gross profit was RMB16.7 million (US$2.5 million), compared to RMB19.4 million last year. Gross profit margin improved to 32.9%, up 1.8 percentage points from 31.1% in the prior year, mainly due to improved margins in the other vaccines segment. Net loss was RMB22.2 million (US$3.3 million), a decrease from RMB25.6 million last year. Basic and diluted loss per share was RMB0.40 (US$0.06), compared to RMB0.46 in the prior year. Revenue from swine vaccines was RMB38.2 million (US$5.6 million), poultry vaccines RMB6.5 million (US$1.0 million), and other vaccines RMB6.2 million (US$0.9 million). Cost of revenue was RMB34.2 million (US$5.0 million), down from RMB42.9 million last year. Total operating expenses were RMB37.6 million (US$5.5 million), down from RMB48.3 million. Sales and marketing expenses were RMB18.6 million (US$2.7 million), general and administrative expenses RMB13.7 million (US$2.0 million), and research and development expenses RMB4.8 million (US$0.7 million). As of June 30, 2026, the company had cash of RMB31.9 million (US$4.7 million), compared to RMB50.3 million as of December 31, 2025. Net cash used in operating activities was RMB16.8 million (US$2.5 million), net cash used in investing activities was RMB5.7 million (US$0.8 million), and net cash provided by financing activities was RMB4.6 million (US$0.7 million). The company’s products are exported to Vietnam, Pakistan, and Egypt. The company operates three veterinary vaccine production floors with 13 production lines, a quality examination center, and an animal facility for vaccine development. The exchange rate used for currency translation was RMB6.7851 to US$1.00 as of June 30, 2026. The company’s gross profit margin for swine vaccines was 44.3%, for poultry vaccines negative 2.9%, and for other vaccines 0.4% for the six months ended June 30, 2026. The company’s total assets as of June 30, 2026, were RMB411.99 million (US$60.72 million), and total liabilities were RMB128.57 million (US$18.95 million). Shareholders’ equity was RMB229.79 million (US$33.87 million), and noncontrolling interests were RMB53.62 million (US$7.90 million). The company’s operating loss was RMB20.8 million (US$3.1 million) for the six months ended June 30, 2026. The company’s products are available in 29 provincial regions across China and are exported to Vietnam, Pakistan, and Egypt.

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

(NASDAQ: ZYBT) Zhengye Biotechnology Holding Limited announced that on August 5, 2026, it received a Compliance Letter from The Nasdaq Stock Market LLC informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). On May 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid price of the Company’s Class A ordinary shares had been below $1.00 per share for 30 consecutive business days. For the last 10 consecutive business days, from July 20, 2026 to August 4, 2026, the closing bid price of the Company’s Class A ordinary shares has been at $1.00 per share or greater. Zhengye continues to be listed on The Nasdaq Capital Market under the ticker symbol “ZYBT”. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs, and its products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The operating entity has three veterinary vaccine production floors (including 13 vaccine production lines), one quality examination center, and one animal facility for vaccine development. The company states that all facilities are operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC.

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT), a veterinary vaccine manufacturer based in China, reported its financial results for the fiscal year ended December 31, 2025. Net revenue was RMB116.4 million (US$16.6 million), down 37.6% from RMB186.4 million in 2024, primarily due to a downturn in the hog market and government policies affecting swine vaccine demand. The company posted a net loss of RMB83.0 million (US$11.9 million) compared to net income of RMB13.5 million in 2024, with gross profit margin dropping to 20.5% from 49.0%. Despite these challenges, Zhengye achieved regulatory milestones, expanded its product portfolio, and ended the year with a stronger cash position of RMB50.3 million (US$7.2 million). The company is pursuing international expansion, particularly in Egypt, Pakistan, and Vietnam.